IDEXX Laboratories, Inc. (NASDAQ:IDXX) Shares Bought by Welch & Forbes LLC

Welch & Forbes LLC lifted its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 0.0% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 169,319 shares of the company’s stock after acquiring an additional 82 shares during the quarter. Welch & Forbes LLC owned 0.21% of IDEXX Laboratories worth $70,003,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also modified their holdings of IDXX. Flossbach Von Storch SE increased its position in shares of IDEXX Laboratories by 5,439.3% during the fourth quarter. Flossbach Von Storch SE now owns 473,336 shares of the company’s stock worth $195,696,000 after acquiring an additional 464,791 shares during the period. Assenagon Asset Management S.A. increased its position in shares of IDEXX Laboratories by 265.6% during the fourth quarter. Assenagon Asset Management S.A. now owns 435,049 shares of the company’s stock worth $179,867,000 after acquiring an additional 316,048 shares during the period. Seilern Investment Management Ltd purchased a new stake in shares of IDEXX Laboratories during the fourth quarter worth $113,104,000. Vontobel Holding Ltd. increased its position in shares of IDEXX Laboratories by 90.1% during the fourth quarter. Vontobel Holding Ltd. now owns 418,563 shares of the company’s stock worth $173,051,000 after acquiring an additional 198,404 shares during the period. Finally, Raymond James Financial Inc. purchased a new position in IDEXX Laboratories in the fourth quarter valued at $71,893,000. Hedge funds and other institutional investors own 87.84% of the company’s stock.

Insider Transactions at IDEXX Laboratories

In other news, EVP George Fennell sold 9,986 shares of the stock in a transaction dated Monday, February 10th. The shares were sold at an average price of $462.53, for a total transaction of $4,618,824.58. Following the completion of the sale, the executive vice president now owns 8,176 shares in the company, valued at approximately $3,781,645.28. This represents a 54.98 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director M Anne Szostak sold 3,000 shares of the stock in a transaction dated Friday, February 7th. The stock was sold at an average price of $465.94, for a total transaction of $1,397,820.00. Following the sale, the director now owns 3,061 shares of the company’s stock, valued at $1,426,242.34. This trade represents a 49.50 % decrease in their position. The disclosure for this sale can be found here. Insiders own 2.11% of the company’s stock.

Analysts Set New Price Targets

Several research firms recently commented on IDXX. Morgan Stanley dropped their target price on IDEXX Laboratories from $559.00 to $550.00 and set an “overweight” rating on the stock in a report on Wednesday, January 29th. Leerink Partners began coverage on IDEXX Laboratories in a report on Monday, December 2nd. They issued an “outperform” rating and a $500.00 target price on the stock. Barclays increased their target price on IDEXX Laboratories from $481.00 to $520.00 and gave the company an “overweight” rating in a report on Tuesday, February 4th. Piper Sandler increased their target price on IDEXX Laboratories from $435.00 to $510.00 and gave the company a “neutral” rating in a report on Monday, February 10th. Finally, Bank of America increased their target price on IDEXX Laboratories from $475.00 to $535.00 and gave the company a “neutral” rating in a report on Tuesday, February 4th. Four research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $533.75.

IDEXX Laboratories Stock Performance

NASDAQ IDXX opened at $429.03 on Friday. IDEXX Laboratories, Inc. has a 1 year low of $398.50 and a 1 year high of $574.94. The company has a market capitalization of $34.89 billion, a PE ratio of 40.21, a P/E/G ratio of 3.41 and a beta of 1.37. The company has a fifty day moving average of $437.06 and a two-hundred day moving average of $450.19. The company has a debt-to-equity ratio of 0.28, a current ratio of 1.31 and a quick ratio of 0.95.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.